Fig. 8From: Chemo-informatics activity prediction, ligand based drug design, Molecular docking and pharmacokinetics studies of some series of 4, 6-diaryl-2-pyrimidinamine derivatives as anti-cancer agents3D structure of the designed compound 1 interactions with VEGFR-2 receptorBack to article page